Foundayo (Orforglipron) Tablets

Foundayo is currently only available in the US and is not yet licensed for prescription in the UK. Once approved by the MHRA, UK patients will typically need a consultation with a registered prescriber, who will assess suitability based on medical history, current medications, and weight management goals before Foundayo can be prescribed.

UK pricing for Foundayo has not yet been confirmed, as the medicine is still awaiting MHRA approval. Once licensed, the manufacturer will set a UK list price, and pharmacies will confirm their own costs.

Both Foundayo and the Wegovy tablet (oral semaglutide) are taken as daily pills, but they work slightly differently. Foundayo comes from Eli Lilly, while the Wegovy tablet is made by Novo Nordisk.

Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist developed by Eli Lilly. The active ingredient was originally discovered by Chugai Pharmaceutical, a Japanese research company, before being developed further by Lilly through large-scale international clinical trials.

Side effects of Foundayo, such as nausea, diarrhoea, or constipation, are usually mild to moderate and most common when starting treatment or increasing the dose. They tend to settle within a few days to a couple of weeks as the body adjusts. Your prescriber may recommend a slower dose increase if side effects persist.

No. While orforglipron is sometimes nicknamed the “Mounjaro pill” because it’s made by the same manufacturer, Foundayo works differently. Mounjaro targets two hormone receptors (GIP and GLP-1), while Foundayo targets only the GLP-1 receptor. Both are designed to support weight loss, but their mechanisms and dosing structures differ.